Introduction of nirsevimab in Catalonia, Spain: description of the incidence of bronchiolitis and respiratory syncytial virus in the 2023/2024 season
Respiratory syncytial virus (RSV) causes most of the cases of bronchiolitis and thousands of deaths annually, particularly in infants less than 6 months old. In Catalonia (Spain), infants born between April 2023 and March 2024 aged 0–6 months during their frst RSV season have been candidates to rece...
| Autores: | , , , , , , , , , , |
|---|---|
| Tipo de documento: | artigo |
| Data de publicação: | 2024 |
| País: | España |
| Recursos: | Universitat Politècnica de Catalunya (UPC) |
| Repositório: | UPCommons. Portal del coneixement obert de la UPC |
| Idioma: | inglês |
| OAI Identifier: | oai:upcommons.upc.edu:2117/417781 |
| Acesso em linha: | https://hdl.handle.net/2117/417781 https://dx.doi.org/10.1007/s00431-024-05779-x |
| Access Level: | Acceso aberto |
| Palavra-chave: | Nirsevimab RSV Respiratory syncytial virus Bronchiolitis Epidemiology Infants Àrees temàtiques de la UPC::Ciències de la salut |
| id |
ES_1957b254e9cb9aa4de6213508e1c43e4 |
|---|---|
| oai_identifier_str |
oai:upcommons.upc.edu:2117/417781 |
| network_acronym_str |
ES |
| network_name_str |
España |
| repository_id_str |
|
| dc.title.none.fl_str_mv |
Introduction of nirsevimab in Catalonia, Spain: description of the incidence of bronchiolitis and respiratory syncytial virus in the 2023/2024 season |
| title |
Introduction of nirsevimab in Catalonia, Spain: description of the incidence of bronchiolitis and respiratory syncytial virus in the 2023/2024 season |
| spellingShingle |
Introduction of nirsevimab in Catalonia, Spain: description of the incidence of bronchiolitis and respiratory syncytial virus in the 2023/2024 season Perramon Malavez, Aida|||0000-0002-6057-5127 Nirsevimab RSV Respiratory syncytial virus Bronchiolitis Epidemiology Infants Àrees temàtiques de la UPC::Ciències de la salut |
| title_short |
Introduction of nirsevimab in Catalonia, Spain: description of the incidence of bronchiolitis and respiratory syncytial virus in the 2023/2024 season |
| title_full |
Introduction of nirsevimab in Catalonia, Spain: description of the incidence of bronchiolitis and respiratory syncytial virus in the 2023/2024 season |
| title_fullStr |
Introduction of nirsevimab in Catalonia, Spain: description of the incidence of bronchiolitis and respiratory syncytial virus in the 2023/2024 season |
| title_full_unstemmed |
Introduction of nirsevimab in Catalonia, Spain: description of the incidence of bronchiolitis and respiratory syncytial virus in the 2023/2024 season |
| title_sort |
Introduction of nirsevimab in Catalonia, Spain: description of the incidence of bronchiolitis and respiratory syncytial virus in the 2023/2024 season |
| dc.creator.none.fl_str_mv |
Perramon Malavez, Aida|||0000-0002-6057-5127 López de Rioja, Víctor|||0000-0003-4485-0616 Coma, Ermengol Hermosilla, Eduardo Fina, Francesc Martínez-Marcos, Montserrat Mendioroz Peña, Jacobo Cabezas Peña, Carmen Montañola Sales, Cristina|||0000-0001-5893-3709 Prats Soler, Clara|||0000-0002-1398-7559 Soriano-Arandes, Antoni |
| author |
Perramon Malavez, Aida|||0000-0002-6057-5127 |
| author_facet |
Perramon Malavez, Aida|||0000-0002-6057-5127 López de Rioja, Víctor|||0000-0003-4485-0616 Coma, Ermengol Hermosilla, Eduardo Fina, Francesc Martínez-Marcos, Montserrat Mendioroz Peña, Jacobo Cabezas Peña, Carmen Montañola Sales, Cristina|||0000-0001-5893-3709 Prats Soler, Clara|||0000-0002-1398-7559 Soriano-Arandes, Antoni |
| author_role |
author |
| author2 |
López de Rioja, Víctor|||0000-0003-4485-0616 Coma, Ermengol Hermosilla, Eduardo Fina, Francesc Martínez-Marcos, Montserrat Mendioroz Peña, Jacobo Cabezas Peña, Carmen Montañola Sales, Cristina|||0000-0001-5893-3709 Prats Soler, Clara|||0000-0002-1398-7559 Soriano-Arandes, Antoni |
| author2_role |
author author author author author author author author author author |
| dc.subject.none.fl_str_mv |
Nirsevimab RSV Respiratory syncytial virus Bronchiolitis Epidemiology Infants Àrees temàtiques de la UPC::Ciències de la salut |
| topic |
Nirsevimab RSV Respiratory syncytial virus Bronchiolitis Epidemiology Infants Àrees temàtiques de la UPC::Ciències de la salut |
| description |
Respiratory syncytial virus (RSV) causes most of the cases of bronchiolitis and thousands of deaths annually, particularly in infants less than 6 months old. In Catalonia (Spain), infants born between April 2023 and March 2024 aged 0–6 months during their frst RSV season have been candidates to receive nirsevimab, the novel monoclonal antibody against RSV, since October 2023. We aimed to analyse the dynamics of all-causes bronchiolitis diagnoses and RSV community infections in the current season and compare them to pre-nirsevimab epidemics. We collected epidemiological data from the Information System for Surveillance of Infections in Catalonia (SIVIC) on daily all-causes bronchiolitis clinical diagnoses and RSV-confrmed cases provided by rapid antigen tests in primary care practices. We calculated the rate ratio (RR) for the incidence of all-causes bronchiolitis for children aged 0-11 m-old with respect to 12-35 m-old between September 2014 and January 2024. We analysed the RR of the incidence of RSV-confrmed infection for 0-11 m-old and 12-35 m-old with respect to the>35 m-old, from January 2021 to January 2024. We then computed the relative diference of the RR, designated as percentage of reduction of risk, between season 2023/2024 and former epidemics. With a global coverage recorded rate for nirsevimab of 82.2% in January 2024, the age-specifc 0-11 m-old RR (95% CI) of RSV infection incidence for>35 m-old was 1.7 (1.5–2.0) in season 2023/2024. The RR (95% CI) had been 7.4 (5.6–9.9), 8.8 (6.9–11.3), and 7.1 (5.7–8.9) in 2020/2021, 2021/2022, and 2022/2023, respectively. Regarding the incidence of all-causes bronchiolitis for the 0-11 m-old group compared to the 12-35 m-old, the pre-pandemic (2014/2015–2019/2020) and 2022/2023 RR (95% CI) were 9.4 (9.2–9.6) and 6.0 (5.7–6.2), respectively, signifcantly higher than the RR of 3.6 (3.4–3.8) for the most recent season, 2023/2024. Conclusion: Concurring with the introduction of nirsevimab, the risk of RSV infection for infants aged 0-11 m-old compared to>35 m-old has been reduced by 75.6% (73.4–77.5) in last season, and the risk for all-causes bronchiolitis for 12-35 m-old by 61.9% (60.9–62.9) from the pre-pandemic period and by 39.8% (39.3–40.2) from the 2022/2023 epidemic, despite high RSV community transmission, especially in older infants. |
| publishDate |
2024 |
| dc.date.none.fl_str_mv |
2024 2024-09-28 2024 2024-11-14 |
| dc.type.none.fl_str_mv |
journal article http://purl.org/coar/resource_type/c_6501 VoR http://purl.org/coar/version/c_970fb48d4fbd8a85 |
| dc.type.openaire.fl_str_mv |
info:eu-repo/semantics/article |
| format |
article |
| dc.identifier.none.fl_str_mv |
https://hdl.handle.net/2117/417781 https://dx.doi.org/10.1007/s00431-024-05779-x |
| url |
https://hdl.handle.net/2117/417781 https://dx.doi.org/10.1007/s00431-024-05779-x |
| dc.language.none.fl_str_mv |
Inglés eng |
| language_invalid_str_mv |
Inglés |
| language |
eng |
| dc.relation.none.fl_str_mv |
Agencia Estatal de Investigación http://doi.org/10.13039/501100011033 Plan Estatal de Investigación Científica y Técnica y de Innovación 2021-2023 PID2022-139215NB-I00 MODELIZACION ESTOCASTICA DE PROCESOS BIOFISICOS A DIFERENTES ESCALAS Ministerio de Ciencia e Innovación http://doi.org/10.13039/501100004837 PTQ-09-02-02134 PTQ-09-02-02134 |
| dc.rights.none.fl_str_mv |
open access http://purl.org/coar/access_right/c_abf2 |
| dc.rights.openaire.fl_str_mv |
info:eu-repo/semantics/openAccess |
| rights_invalid_str_mv |
open access http://purl.org/coar/access_right/c_abf2 |
| eu_rights_str_mv |
openAccess |
| dc.format.none.fl_str_mv |
application/pdf |
| dc.publisher.none.fl_str_mv |
Springer |
| publisher.none.fl_str_mv |
Springer |
| dc.source.none.fl_str_mv |
reponame:UPCommons. Portal del coneixement obert de la UPC instname:Universitat Politècnica de Catalunya (UPC) |
| instname_str |
Universitat Politècnica de Catalunya (UPC) |
| reponame_str |
UPCommons. Portal del coneixement obert de la UPC |
| collection |
UPCommons. Portal del coneixement obert de la UPC |
| repository.name.fl_str_mv |
|
| repository.mail.fl_str_mv |
|
| _version_ |
1869404040450801664 |
| spelling |
Introduction of nirsevimab in Catalonia, Spain: description of the incidence of bronchiolitis and respiratory syncytial virus in the 2023/2024 seasonPerramon Malavez, Aida|||0000-0002-6057-5127López de Rioja, Víctor|||0000-0003-4485-0616Coma, ErmengolHermosilla, EduardoFina, FrancescMartínez-Marcos, MontserratMendioroz Peña, JacoboCabezas Peña, CarmenMontañola Sales, Cristina|||0000-0001-5893-3709Prats Soler, Clara|||0000-0002-1398-7559Soriano-Arandes, AntoniNirsevimabRSVRespiratory syncytial virusBronchiolitisEpidemiologyInfantsÀrees temàtiques de la UPC::Ciències de la salutRespiratory syncytial virus (RSV) causes most of the cases of bronchiolitis and thousands of deaths annually, particularly in infants less than 6 months old. In Catalonia (Spain), infants born between April 2023 and March 2024 aged 0–6 months during their frst RSV season have been candidates to receive nirsevimab, the novel monoclonal antibody against RSV, since October 2023. We aimed to analyse the dynamics of all-causes bronchiolitis diagnoses and RSV community infections in the current season and compare them to pre-nirsevimab epidemics. We collected epidemiological data from the Information System for Surveillance of Infections in Catalonia (SIVIC) on daily all-causes bronchiolitis clinical diagnoses and RSV-confrmed cases provided by rapid antigen tests in primary care practices. We calculated the rate ratio (RR) for the incidence of all-causes bronchiolitis for children aged 0-11 m-old with respect to 12-35 m-old between September 2014 and January 2024. We analysed the RR of the incidence of RSV-confrmed infection for 0-11 m-old and 12-35 m-old with respect to the>35 m-old, from January 2021 to January 2024. We then computed the relative diference of the RR, designated as percentage of reduction of risk, between season 2023/2024 and former epidemics. With a global coverage recorded rate for nirsevimab of 82.2% in January 2024, the age-specifc 0-11 m-old RR (95% CI) of RSV infection incidence for>35 m-old was 1.7 (1.5–2.0) in season 2023/2024. The RR (95% CI) had been 7.4 (5.6–9.9), 8.8 (6.9–11.3), and 7.1 (5.7–8.9) in 2020/2021, 2021/2022, and 2022/2023, respectively. Regarding the incidence of all-causes bronchiolitis for the 0-11 m-old group compared to the 12-35 m-old, the pre-pandemic (2014/2015–2019/2020) and 2022/2023 RR (95% CI) were 9.4 (9.2–9.6) and 6.0 (5.7–6.2), respectively, signifcantly higher than the RR of 3.6 (3.4–3.8) for the most recent season, 2023/2024. Conclusion: Concurring with the introduction of nirsevimab, the risk of RSV infection for infants aged 0-11 m-old compared to>35 m-old has been reduced by 75.6% (73.4–77.5) in last season, and the risk for all-causes bronchiolitis for 12-35 m-old by 61.9% (60.9–62.9) from the pre-pandemic period and by 39.8% (39.3–40.2) from the 2022/2023 epidemic, despite high RSV community transmission, especially in older infants.Open Access funding provided thanks to the CRUE-CSIC agreement with Springer Nature. The author(s) declare financial sup- port was received for the research, authorship, and/or publication of this article. ASA has received honoraria for attending scientific meetings from Sanofi, MSD, and Pfizer. Funding was also received from grant number 202134–30-31, funded by “La Fundació La Marató de TV3”, and grant PDI2022-139215NB-I00 funded by MCIN/AEI/https://doi. org/10.13039/501100011033and by “ERDF A way of making Europe”.Peer ReviewedObjectius de Desenvolupament Sostenible::3 - Salut i BenestarSpringer20242024-09-2820242024-11-14journal articlehttp://purl.org/coar/resource_type/c_6501VoRhttp://purl.org/coar/version/c_970fb48d4fbd8a85info:eu-repo/semantics/articleapplication/pdfhttps://hdl.handle.net/2117/417781https://dx.doi.org/10.1007/s00431-024-05779-xreponame:UPCommons. Portal del coneixement obert de la UPCinstname:Universitat Politècnica de Catalunya (UPC)InglésengAgencia Estatal de Investigación http://doi.org/10.13039/501100011033 Plan Estatal de Investigación Científica y Técnica y de Innovación 2021-2023 PID2022-139215NB-I00 MODELIZACION ESTOCASTICA DE PROCESOS BIOFISICOS A DIFERENTES ESCALASMinisterio de Ciencia e Innovación http://doi.org/10.13039/501100004837 PTQ-09-02-02134 PTQ-09-02-02134open accesshttp://purl.org/coar/access_right/c_abf2info:eu-repo/semantics/openAccessoai:upcommons.upc.edu:2117/4177812026-05-27T15:37:01Z |
| score |
15,198674 |